With partner Sanofi SA, Regeneron Pharmaceuticals Inc. opened investors' eyes wider by making public the positive outcomes of nine phase III trials with alirocumab, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in hypocholesterolemia. Read More
Reporting after the markets closed Tuesday, the industry's second largest biotech company by market cap, Amgen Inc., not only provided exceptionally strong second quarter financial results but also revealed its plans for significant corporate changes. The Thousand Oaks, Calif.-based company said it will shed approximately 12 percent to 15 percent of its global work force. Read More
LONDON – Cells and tissues around a tumor may have as much to do with the process by which cancer cells become resistant to chemotherapy or radiotherapy as the cancer cells themselves, a new study suggests. Read More
HONG KONG – The Shanghai No.1 Intermediate People's Court announced Monday the date for the trial of the two investigators allegedly linked to Glaxosmithkline plc's (GSK) bribery scandal in China. Read More
SHANGHAI – Merck KGaA, of Darmstadt, Germany, has reiterated its commitment to China, forging ahead with its €80 million (US$107.3 million) manufacturing plant, expected to be Merck's second largest globally and its first such pharmaceutical investment in China. Read More
A phase II miss testing a combination of cystic fibrosis (CF) drugs in a heterozygous subset of patients with the F508del mutation slightly dented shares of Vertex Pharmaceuticals Inc. Wednesday morning, but the Boston-based biotech beat analyst estimates in the second quarter and looks well positioned to build out its CF franchise going forward. Read More
Sirona Biochem Corp., of Vancouver, British Columbia, entered convertible loan agreements with arm's length parties for the purposes of renewing current outstanding loans in the amount of $670,000. Read More
Orexigen Therapeutics Inc., of San Diego, said it received the Day 180 list of outstanding issues (LOI) from the EMA's Committee for Medicinal Products for Human Use (CHMP) for its marketing authorization application for NB32 (naltrexone sustained-release [SR]/bupropion SR), an investigational drug candidate being evaluated for weight loss. Read More
Eli Lilly and Co., of Indianapolis, said that the EMA's Committee for Medicinal Products for Human Use recommended approval of insulin lispro 200 units/ml (proposed trade name: Humalog 200 units/ml Kwikpen) for the treatment of type 1 and type 2 diabetes in adults. Read More
Atheronova Inc., of Irvine, Calif., said partner Cardionova Ltd., of Moscow, has completed first dosing of subjects for its phase Ib trial testing atherosclerosis candidate AHRO-001. Read More
CSL Behring, of King of Prussia, Pa., said a study presented at the World Transplant Congress in San Francisco showed that C1-INH, its C1 inhibitor, may have use in preventing antibody-mediated rejection following kidney transplants in highly sensitized patients. Read More
